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Cost-eﬀ ectiveness of surgery and its policy implications for 
global health: a systematic review and analysis
Tiﬀ any E Chao, Ketan Sharma, Morgan Mandigo, Lars Hagander, Stephen C Resch, Thomas G Weiser, John G Meara
Summary
Background The perception of surgery as expensive and complex might be a barrier to its widespread acceptance in global 
health eﬀ orts. We did a systematic review and analysis of cost-eﬀ ectiveness studies that assess surgical interventions in 
low-income and middle-income countries to help quantify the potential value of surgery.
Methods We searched Medline for all relevant articles published between Jan 1, 1996 and Jan 31, 2013, and searched 
the reference lists of retrieved articles. We converted all results to 2012 US$. We extracted cost-eﬀ ectiveness ratios 
(CERs) and appraised economic assessments for their methodological quality using the 10-point Drummond 
checklist.
Findings Of the 584 identiﬁ ed studies, 26 met full inclusion criteria. Together, these studies gave 121 independent 
CERs in seven categories of surgical interventions. The median CER of circumcision ($13·78 per disability-adjusted 
life year [DALY]) was similar to that of standard vaccinations ($12·96–25·93 per DALY) and bednets for malaria 
prevention ($6·48–22·04 per DALY). Median CERs of cleft lip or palate repair ($47·74 per DALY), general surgery 
($82·32 per DALY), hydrocephalus surgery ($108·74 per DALY), and ophthalmic surgery ($136 per DALY) were 
similar to that of the BCG vaccine ($51·86–220·39 per DALY). Median CERs of caesarean sections ($315·12 per 
DALY) and orthopaedic surgery ($381·15 per DALY) are more favourable than those of medical treatment for 
ischaemic heart disease ($500·41–706·54 per DALY) and HIV treatment with multidrug antiretroviral therapy 
($453·74–648·20 per DALY).
Interpretation Our ﬁ ndings suggest that many essential surgical interventions are cost-eﬀ ective or very cost-eﬀ ective 
in resource-poor countries. Quantiﬁ cation of the economic value of surgery provides a strong argument for the 
expansion of global surgery’s role in the global health movement. However, economic value should not be the only 
argument for resource allocation—other organisational, ethical, and political arguments can also be made for its 
inclusion.
Funding Massachusetts General Hospital Department of Surgery, Boston Children’s Hospital, and Stanford University 
Department of Surgery. 
Copyright © Chao et al. Open Access article distributed under the terms of CC BY.
Introduction
Global health eﬀ orts, guided in part by the Millennium 
Development Goals (MDGs),1 have focused mainly on the 
prevention and treatment of malnutrition, obstetric 
disorders, and communicable diseases.2 With the exception 
of a few surgical procedures—eg, caesarean delivery and 
male circumcision, which have a role in the prevention of 
maternal and neonatal deaths and the transmission of 
some communicable diseases—surgical interventions 
have been largely ignored. However, ﬁ ndings from the 
Global Burden of Disease 2010 study show that the growing 
burden of both non-communicable diseases and injuries 
includes many surgically treatable problems.3 For example, 
road-traﬃ  c injuries accounted for 75·5 million disability-
adjusted life-years (DALYs) in 2010, up nearly 20 million 
DALYs from 1990. Cancer has caused 76% more disability 
globally in the same timeframe. Historically, surgically 
treatable disease was estimated to account for at least 11% 
of the total global burden of disease,4 which might be an 
underestimate because other studies have reported that 
about 25% of people in Sierra Leone need surgical 
assessment,5 and as many as 85% of paediatric patients in 
Africa have a surgically treatable disorder by the age 
of 15 years.6 The substantial and growing burden of 
surgically treatable disease necessitates careful assessment 
of a wide range of surgical interventions to establish their 
priority within the expanding global health movement.7
The perception of surgery as an expensive intervention 
might be a barrier to widespread acceptance of its potential 
role in achieving global health goals, especially when 
compared with other public health measures such as 
vaccines or antiretroviral treatment.2,8 Assessment of the 
value of surgery in these settings is further challenged by 
uncertainty about the epidemiology of met and unmet 
need worldwide, the eﬀ ectiveness of surgical intervention 
in the prevention of death and disability, and established 
benchmarks for quality of surgical care.9
Cost-eﬀ ectiveness analysis might help to establish the 
value of surgical intervention because it takes into 
account both cost and health impact simultaneously in a 
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validated and transparent framework.10 Mock and 
colleagues proposed that cost-eﬀ ectiveness of surgical 
procedures be considered, along with burden of disease 
and success of surgical intervention, to prioritise various 
surgical interventions in resource-poor countries.11 
Investigators doing cost-eﬀ ectiveness research have 
analysed a range of surgery-related expenditures in low-
income and middle-income settings, from short-term 
volunteer-led projects focusing on procedures for single 
diseases such as cleft palate or cataracts12–14 to the existence 
of surgical facilities15–18 to the potential implementation of 
surgical interventions internationally.19–25 Stakeholders 
and policymakers have to consider a wide variety of 
factors when allocating funds and resources, and they 
would beneﬁ t from improved estimates of the prevalence 
of surgically treatable diseases and better information 
about the cost-eﬀ ectiveness of surgery.
Various metrics have been proposed to calculate the 
health-beneﬁ t component of the cost-eﬀ ectiveness 
equation when assessing a proposed intervention. The 
simplest is life-years (LY) gained, but this metric does not 
account for an intervention’s ability to reduce morbidity. 
Summary measures of health that account for both 
survival and quality-of-life improvements include the 
quality-adjusted life year (QALY),26 handicap-adjusted life 
year (HALY),27 and DALY.28 DALYs are calculated by 
adding the number of years of life lost due to premature 
mortality to the number of years of healthy life lost 
related to disability. Thus one DALY is deﬁ ned as the loss 
of the equivalent of 1 year of life at full health.29 The 
strengths and limitations of the DALY approach have 
been described previously.27,30 Nevertheless, DALYs have 
become the most commonly used metric of health 
impact31,32 and have been promoted by both the Disease 
Control Priorities Project4 and WHO’s Global Burden of 
Disease project.7
The evidence base for the cost-eﬀ ectiveness of surgery in 
low-income and middle-income countries33 is incomplete 
because no study has incorporated rigorous quality 
assessment and analysis.34 We aimed to systematically 
compile and compare the cost-eﬀ ectiveness of diﬀ erent 
surgical interventions, to objectively assess the rigour with 
which such studies were done, and to do a thorough 
analysis of existing data to mediate the divergent ﬁ ndings 
in previous cost-eﬀ ectiveness studies.
Methods
Search strategy and selection criteria
We followed the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines.17 We 
searched Medline using the following MeSH headings: 
“Surgical”, “Surgery”, “Costs and cost analysis”, “Cost-
beneﬁ t analysis” (inclusive of the subheading “cost 
eﬀ ectiveness”), “Health care costs”, and “Developing 
countries”. We identiﬁ ed more articles by consulting 
experts and manually reviewing bibliographies of retrieved 
studies. We did our last search on Jan 31, 2013.
Inclusion criteria were as follows: studies that analysed 
the cost-eﬀ ectiveness or cost-beneﬁ t of surgical pro-
cedures, presence of surgical facilities, or surgical 
missions; measured health beneﬁ t in LYs, QALYs, HALYs 
gained, or DALYs averted; were done in low-income and 
middle-income countries as deﬁ ned by the World Bank;33 
and were published since 1996. Exclusion criteria were 
as follows: any study consisting of a narrative review or 
editorial lacking formal analytic methodology or using a 
diﬀ erent measure of health beneﬁ t.
Quality assessment and data extraction
We appraised economic assessments for their methodol-
ogical quality using the Drummond 10-point checklist, a 
standard method for the assessment of cost-eﬀ ectiveness 
studies.10 Some checklist items have both cost and con-
sequence components; for these items, each component 
is weighted at 0·5 times, such that the ﬁ nal denominator 
is 10. If a component was not applicable, we weighed the 
complementary component at times 1.
We converted results from all studies that described 
cost-eﬀ ectiveness in US$ per DALY, HALY, or QALY 
from their initial values in the study’s reported currency 
to 2012 US$ using the Consumer Price Index Inﬂ ation 
calculator.35 In some studies, the currency year was not 
stated and was therefore assumed to be the year of a 
study’s publication. The studies that used international 
dollars did not include enough detail about what 
fraction of costs were non-tradable—we converted 
these costs into US$ and accordingly compared them 
using the Atlas method gross domestic product (GDP) 
per head.
To extract as much information as possible, we 
separated results from diﬀ erent countries or procedures 
even if they were reported in the same study; we regarded 
these results as separate data points when calculating 
medians. We included values for surgical interventions 
not combined with medical treatments only. We excluded 
data points from high-income countries only. Whenever 
possible, incremental DALY calculations using age 
weighting and 3% discounting were chosen for point 
values, and calculations without discounting and age 
585 unique abstracts identiﬁed
571 through PubMed
14 through manual review
521 abstracts
64 full-text articles extracted
for in-depth review 38 excluded
8 in high-income countries
27 other outcome metric
1 non-surgical
2 reviews
26 articles met ﬁnal
inclusion criteria
Figure 1: Study selection 
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Year Intervention Country GDP per head* Cost per outcome Unit of 
outcome 
Currency Cost per outcome 
in 2012 US$
General or other
Jha et al36 1998 Caesarean delivery; 
appendectomy; 
hernia repair;
trauma
Guinea $313 $18 / caesarean delivery;
$36 / appendectomy;
$74 / hernia;
$278 / severe trauma
LY 1994 US$ $28;
$56;
$115;
$431;
Gosselin et al17 2006 Surgical hospital Sierra Leone $243 $32·78 DALY 2004 US$ $39·84
Debas et al4 2006 Injury, obstetrics, cataracts or 
glaucoma, cancer, perinatal 
conditions, congenital 
anomalies, other
Global $887 $212–241 in community hospital;
$33–94 in district hospital†
DALY 2001 US$ $275–312
$43–122
Gosselin et al15 2008 Trauma hospital Cambodia $479 $77·40 DALY 2006 US$ $88·15
Gosselin et al16 2010 Trauma centre Nigeria;
Haiti
$1280 in Nigeria;
$621 in Haiti
$172 in Nigeria;
$223 in Haiti
DALY 2008 US$ $183;
$238
Shillcutt et al37 2010 Inguinal hernia repair Ghana $1153 $12·88 DALY 2008 US$ $13·73
Warf et al38 2011 Lifetime hydrocephalus repair Uganda $272 $59–126 DALY 2005 US$ $69–148
Shillcutt et al39 2013 Inguinal hernia repair Ecuador $4952 $78·18 DALY 2011 US$ $79·80
Obstetrics
McCord et al18 2003 Obstetric hospital‡ Bangladesh $225 $10·93 DALY 1995 US$ $16·47
Alkire et al20 2012 Caesarean delivery 49 countries $734 $304 ($251–3462) DALY 2008 US$ $324 ($268–3692)
Ophthalmology
Evans et al40 1996 Trachoma surgery Burma Data not available $59‡ ($22–70) HALY 1990 US$ $104 ($39–123)
Marseille et al41 1996 Cataract repair Nepal $155 $5·06† DALY 1996 US$ $7·40
Baltussen et al22 2004 Cataract repair Global $876 $54 (southeast Asia D)—$465 
(Europe B)¶ 
DALY 2000 
international $
$72–620
Baltussen et al23 2005 Trachoma surgery Global $876 $13–17 in Africa;
$36–78 in Eastern Mediterranean; 
$49 in the Americas;
$24 in southeast Asia;
$35 in Western Paciﬁ c
DALY 2000 
international $
$17–23;
$48–104;
$65;
$32;
$47 
Lansingh et al25 2009 Cataract repair Brazil;
China;
Ethiopia;
India;
Kenya;
Nepal;
Nigeria;
Uganda
Zimbabwe
$3027 in Brazil; 
$1251 in China;
$114 in Ethiopia; 
$546 in India; 
$388 in Kenya;
$245 in Nepal; 
$542 in Nigeria
$240 Uganda
$384 Zimbabwe
$60·9 in Brazil
$253·6–834 China
$13·8 in Ethiopia
$3·7–35·1 in India
$25 in Kenya
$3·5–35·7 in Nepal 
$36·1 in Nigeria 
$27·9 in Uganda
$55·4 in Zimbabwe
QALY 2004 US$ $74·0;
$308·2–1013·7;
$16·8;
$4·5–42·7;
$30·4;
$4·3–43·4;
$43·9
$33·9
$67·3
Wittenborn et al42 2011 Glaucoma surgery Barbados;
Ghana
$9514 in Barbados;
$435 in Ghana
$1272–6632 in Barbados;
$1407–9808 in Ghana||
DALY 2005 US$ $1495–7797
$1654–11 530
Baltussen et al21 2012 Trachoma and trichiasis surgery, 
cataract repair
Sub-Saharan 
Africa (SSA);
southeast 
Asia (SEA)
$359 in SSA;
$641 in SEA
$71–189 for trachoma in SSA; 
$285–849 for trachoma in SEA;
$116–117 for cataract repair in SSA; 
$97 for cataract repair in SEA
DALY 2005 
international $
$83–222;
$335–998;
$136–138;
$114
Orthopaedics
Gosselin et al14 2011 Orthopaedic repair Haiti; 
Dominican 
Republic and 
Nicaragua
$639 in Haiti;
$3160 in Dominican 
Republic and 
Nicaragua
$343 in Haiti;
$362 Dominican Republic and 
Nicaragua
DALY 2010 US$ $361;
$381
Chen et al12 2012 Orthopaedic repair Nicaragua $1406 $476·32 DALY 2010 US$ $501·52
Plastic surgery
Corlew et al24 2010 Cleft lip and palate repair Nepal $278 $29 DALY 2005 US$ $34
Magee et al43 2010 Cleft lip and palate repair Kenya;
Russia;
Nicaragua;
Vietnam
$734 in Kenya;
$10933 in Russia;
$1361 in Nicaragua;
$1000 in Vietnam
$96·04 in Kenya; 
$32·27 in Russia; 
$66·01 in Nicaragua;
$7·36–23·83 in Vietnam
DALY 2008 US$ $102·41;
$34·41;
$70·39;
$7·85–25·41
Moon et al13 2012 Cleft lip and palate repair Vietnam $1167 $56** ($43–65) DALY 2007–
2010 US$
$59 ($45–68)
(Table 1 continues on next page)
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1 2 3 4 5a 5b 6a 6b 7a 7b 8 9 10 Summary score
Baltussen et al (2004) Y Y Y Y Y Y Y Y Y Y Y Y Y 10
Baltussen et al (2005) Y Y Y Y Y Y Y Y Y Y Y Y Y 10
Binagwaho et al (2010) Y Y Y Y Y Y Y Y Y Y Y Y Y 10
Baltussen et al (2012) Y Y Y Y Y Y Y Y N/A Y Y Y Y 10
Evans et al (1996) Y Y Y Y Y Y Y N Y Y Y Y Y 9·5
Uthman et al (2011) Y Y Y Y Y Y N Partially Y Y Y Y Y 9·25
Marseille et al (1996) Y Y Y Y Y Y Y Y N/A Y N Y Y 9
Warf et al (2011) Y Y Y Y Y Y Y Y Y Y N Y Y 9
Wittenborn et al (2011) Y Y Y N Y Y N Y N/A Y Y Y Y 8·5
Shillcutt et al (2012) Y Y Partially Y Y Y Y Y N/A Y N Y Y 8·5
Kahn et al (2006) Y Y Y N Y Y N Partially Y Y Y Y Y 8·25
Jha et al (1998) Y Y Y Y Y Y Y Y N/A Y N N Y 8
Lansingh et al (2009) Y Y N Y Y Y Y Y Y Y N Y Y 8
Shillcutt et al (2010) Y Y N Y Y Y Y Y N/A Y N Y Y 8
Moon et al (2012) Y Y N Y Y Y Y Y N/A Y N Y Y 8
McCord et al (2003) Y Y Partially Y Y Y Y Y N/A Y N N Y 7·5
Gosselin et al (2008) Y Y Partially Y Y Y Y Y N/A Y N N Y 7·5
Gosselin et al (2010) Y Y Partially Y Y Y Y Y N/A Y N N Y 7·5
Gosselin et al (2006) Y Y Partially Y Y Y Y Partially N/A Y N N Y 7·25
Alkire et al (2012) Y Y N N Y Y Y Y N/A Y N Y Y 7
Chen et al (2012) Y Y N N Y Y Y Y N/A Y N Y Y 7
Fieno et al (2008) Y Y Y Y Y Y Y Partially N/A N N N Y 6·75
Magee et al (2010) Y Y Y N Y Y N Y N/A Y N Y N 6·5
Debas et al (2006) N Y N Y Y Y Y N N/A N N Y Y 6
Corlew et al (2010) N Y N N Y Y Y Y N/A Y N Y N 5
Gosselin et al (2011) Y Y Partially N Y Y N Y N/A N N N Y 4·5
Drummond checklist questions are: 1= Was a well-deﬁ ned question posed in answerable form?; 2=Was a comprehensive description of the competing alternatives given?; 3=Was the eﬀ ectiveness of the 
programme or services established?; 4=Were all the important and relevant costs and consequences for each alternative identiﬁ ed?; 5a=Were costs measured accurately in appropriate physical units?; 5b=Were 
consequences measured accurately in appropriate physical units?; 6a=Were the cost valued credibly?; 6b=Were the consequences valued credibly?; 7b=Were costs adjusted for diﬀ erential timing? 8=Was an 
incremental analysis of costs and consequences of alternatives done?; 9=Was allowance made for uncertainty in the estimates of costs and consequences?; 10=Did the presentation and discussion of study results 
include all issues of concern to users?
Table 2: Drummond scoring
Year Intervention Country GDP per head* Cost per outcome Unit of 
outcome 
Currency Cost per outcome 
in 2012 US$
(Continued from previous page)
Urology††
Kahn et al44 2006 Adult male circumcision South Africa $4882 CER $12·10; <$0†† DALY 2006 US$ $13·78
Fieno et al45 2008 Adult male circumcision Mozambique $406 CER $7·38; <$0†† DALY 2008 US$ $7·87
Binagwaho et al46 2010 Male circumcision Rwanda $431 $334 for adolescents; $613 for adults LY‡‡ 2008 US$ $356;
$654
Uthman et al47 2011 Adult male circumcision SSA $1142 CER $19·71; <$0†† DALY 2008 US$ $21·02
DALY=disability-adjusted life-year. HALY=handicap-adjusted life-year. QALY=quality-adjusted life-year. LY=life-year. *Country or regional gross domestic product (GDP) per head from World Bank in the same US$ as year of 
currency; calculations done on Dec 8, 2013, using 2013 index of 106.2; low-income and middle-income GDP data used for global studies—for multiple countries, we report the median value. †We report best estimates—see 
original study for low and high estimates. ‡Interventions include medical, obstetric or gynaecological, paediatric, and surgical care, although obstetric or gynaecological and surgical interventions constituted majority of 
care. §Represents reported mean of values across all phases of implementation. ¶Across all coverage scenarios, including both surgical methods; regions containing only upper-income countries excluded. ||Range 
represents three diﬀ erent case-ﬁ nding models and one-time surgical laser treatment. **Represents reported mean of point values across all mission years. ††This cost-eﬀ ectiveness ratio (CER) represents the incremental 
cost per DALY averted compared with no circumcision, wherein corresponding costs of HIV treatment are provided for HIV infections not averted by circumcision. ‡‡Outcome is LYs gained by averting HIV infection, with 
correction for the number of years (22 years) that would be achieved with anti-retroviral therapy. Geographical regions A–E are deﬁ ned based on epidemiological similarity,22 such that B=low adult mortality and 
low child mortality and D=high adult mortality and high child mortality.
Table 1: Studies of surgical interventions
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weighting were excluded from analysis. When diﬀ erent 
costs were provided, we excluded estimates that included 
consumables but did not account for infrastructure. We 
calculated median values for interventions for which 
cost-eﬀ ectiveness was reported in DALYs, HALYs, or 
QALYs.
We extracted cost-eﬀ ectiveness ratios (CERs) for non-
surgical global health interventions from Disease 
Control Priorities for Developing Countries.48 These 
values incorporate the CER with respect to the individual 
receiving the intervention and were derived from com-
prehensive literature searches to incorporate all available 
analyses. As such, these estimates are aﬀ ected by the 
same variability in costing methodology as the data 
reported herein for surgical interventions; however, we 
applied the same discounting and age-weighting.
TEC and LH reviewed abstracts and TEC reviewed 
full articles to assess eligibility for inclusion, with 
disagreements resolved by discussion. TEC, KS, and MM 
abstracted study information and additional data to 
create tables and ﬁ gures. TEC and KS assessed study 
quality using the Drummond 10-point checklist. We did 
iterative reviews until consensus was reached about key 
messages and conclusions.
Statistical analysis
The appendix details the data extracted from each 
reference to generate point values and ranges for the 
surgical interventions identiﬁ ed. Quantitative synthesis 
was done by extracting or calculating median values for 
each intervention.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
We identiﬁ ed 571 citations in our systematic review, 
adding an additional 14 after manual review. Of these, 
26 met full inclusion criteria (ﬁ gure 1). The 26 included 
studies4,12–18,20–25,36–47 were published between 1996 and 2012 
(table 1). The appendix and table 2 show the results of 
the assessment of each study with the Drummond 
checklist.
We extracted and converted to 2012 US$ 121 
independent CERs in seven categories of surgical inter-
ventions. The most cost-eﬀ ective procedures included 
$7·87 per DALY for male circumcision in Mozambique,45 
and $7·29 per DALY for cataract repair in Nepal.25 Of the 
121 interventions assessed, only ﬁ ve estimates exceeded 
$1000 per DALY: glaucoma surgery in Barbados 
($1451·91–7570·02) and Ghana ($1606·00–11 195·22),42 
and caesarean deliveries in Mongolia ($1085·61), 
Tunisia ($2150·88), and Libya ($3077·56).20 However, 
two of these ﬁ ve countries, Tunisia and Libya, are upper-
middle-income countries.
The median CERs ($ per DALY averted) for speciﬁ c 
interventions were $13·78 for adult male circumcisions; 
$47·74 for cleft lip and palate repair; $82·32 for general 
surgery, including interventions done at surgical hospitals; 
$108·74 for hydrocephalus repair;38 $136·00 for ophthalmic 
surgery, including cataract, trichiasis, and trachoma 
surgery; $315·12 for caesarean deliveries; and $381·15 for 
orthopaedic surgery done at elective and emergency 
mission settings (ﬁ gures 2, 3, and 4).
We also calculated CERs for adult male circumcision by 
comparing the cost per DALY attributed to averted HIV 
infections with the cost per DALY for HIV treatment in 
view of the higher incidence in uncircumcised men. 
Providing surgical services at a
community clinic (global)4
Trauma centre (Haiti)16
Trauma centre (Nigeria)16
Trauma hospital (Cambodia)15
Providing surgical services at a
district hospital (global)4
Inguinal hernia repair (Ecuador)39
Surgical hospital (Sierra Leone)17
Community hospital with
surgical services (Bangladesh)18
Inguinal hernia repair (Ghana)37
0·00 50·00 100·00 150·00 200·00 250·00 300·00 350·00 400·00
C General surgery
D Orthopaedic surgery
274·84 312·43
237·80
7·85 25·41
45·28 68·44
102·41
21·02
13·78
7·87
34·41
34·09
70·39
183·42
88·15
42·78 121·86
79·80
39·84
16·47
13·73
Mission trip (Kenya)43
Mission trip (Nicaragua)43
Mission trip (Vietnam)13
Mission trip (Russia)43
Hospital Cleft Center (Nepal)24
Mission trip (Vietnam)43
0 20 40 60 80 100 120
B Cleft lip and palate repair
Sub-Saharan Africa47
South Africa44
Mozambique45
0 10 20 30
A Adult male circumcision
Elective mission (Nicaragua)12
Elective mission (Dominican
Republic and Nicaragua)14
Relief mission (Haiti)14
0 100 200 300 400 500 600
$ per DALY averted (2012 US$)
501·52
381·15
361·15
Figure 2: Cost-eﬀ ectiveness ratios for adult circumcision (A), cleft lip and palate repair (B), general surgery (C), 
and orthopaedic surgery (D)
DALY=disability-adjusted life-year.
See Online for appendix
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335·05 998·08
497·32 619·98
393·32 459·99
338·66
351·99 415·99
466·65
291·99 413·32
286·66 375·99
250·66 270·66
250·66 297·33
210·66 253·33
206·66 245·33
185·33 221·33
180 250·66
154·66 222·66
158·66 209·33
83·47 222·19
141·33 168
125·33 144
118·66 142·66
38·65 122·97
104
74·02
72 82·66
132
114·03
144
150·66
136·37 137·54
78·66
67·33
65·33
48
46·67
32
22·67
17·33
7·4
81·33
154·66
0 200
Glaucoma surgery (Ghana)42
Glaucoma surgery (Barbados)42
Cataract repair (China)25
Trachoma surgery (southeast Asia)21
ECCE-PC-IOL cataract repair (Europe C)22
ICCE-AG cataract repair (Europe B)22
ICCE-AG cataract repair (Americas D)22
ICCE-AG cataract repair (Americas B)22
ICCE-AG cataract repair (eastern Mediterranean B)22
ICCE-AG cataract repair (western Paciﬁc B)22
ICCE-AG cataract repair (eastern Mediterranean D)22
ICCE-AG cataract repair (Africa E)22
ICCE-AG cataract repair (Africa D)22
ECCE-PC-IOL cataract repair (Europe C)22
ECCE-PC-IOL cataract repair (Americas D)22
ECCE-PC-IOL cataract repair (Americas B)22
ECCE-PC-IOL cataract repair (eastern Mediterranean B)22
ECCE-PC-IOL cataract repair (western Paciﬁc B)22
ICCE-AG cataract repair (southeast Asia B)22
Trachoma surgery (sub-Saharan Africa)21
ECCE-PC-IOL cataract repair (Africa E)22
Cataract repair (sub-Saharan Africa)21
ECCE-PC-IOL cataract repair (eastern Mediterranean D)22
ICCE-AG cataract repair (southeast Asia D)22
ECCE-PC-IOL cataract repair (Africa D)22
Cataract repair (southeast Asia)21
Trachoma surgery (Burma)40
Trachoma surgery (east Mediterranean B)23
ECCE-PC-IOL cataract repair (southeast Asia B)22
ECCE-PC-IOL cataract repair (southeast Asia D)22
Cataract repair (Brazil)25
Cataract repair (Zimbabwe)25
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Figure 3: Cost-eﬀ ectiveness 
ratios for adult ophthalmic 
surgery
Diamonds are DALYs, triangles 
are QALYs, and squares are 
HALYs. ICCE-AG=intra-capsular 
cataract extraction, using 
aphakic glasses. 
ECCE-PC-IOL=extra-capsular 
cataract extraction with 
implantation of a posterior 
chamber intraocular lens. 
Geographical regions A–E are 
deﬁ ned based on 
epidemiological similarity,22 
such that A=regions with very 
low adult mortality and 
low child mortality, 
B=low adult mortality and 
low child mortality, 
C=high adult mortality and 
low child mortality, 
D=high adult mortality and 
high child mortality, and 
E=very high adult mortality and 
high child mortality.
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Findings from all three studies showed that provision of 
circumcision was cost-saving versus no circumcision, 
yielding a CERs of less than $0. 
Figure 5 shows these values relative to traditional 
public health interventions. The median CERs of surgical 
interventions compare favourably with the selected 
traditional public health strategies in low-income-
countries (adjusted to 2012 US$).35,48
Discussion
Our ﬁ ndings draw attention to the cost-eﬀ ectiveness of 
published surgical interventions, according to both inter-
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Figure 4: Cost-eﬀ ectiveness ratios for caesarean deliveries20
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national standards and in relation to traditional public 
health strategies. WHO has endorsed cost-eﬀ ectiveness 
analysis to help guide policy,49 speciﬁ cally, a system based 
on a country’s GDP per head.50 Interventions with a CER 
one-to-three times greater than the host country’s GDP per 
head are regarded as cost-eﬀ ective, whereas ones with a 
CER lower than GDP per head are regarded as very cost-
eﬀ ective.50 Table 1 shows the GDP per person of the 
countries included in this review and can be used to 
establish each intervention’s cost-eﬀ ectiveness based on 
these criteria. These values are reported in US$ in the 
corresponding year of the study’s reported currency.51 
According to this WHO deﬁ nition for cost-eﬀ ectiveness, 
nearly all surgical interventions reported here are very cost 
eﬀ ective. 52
The wide range of cost-eﬀ ectiveness for similar 
procedures shows regional variation in price, demo-
graphics, and resource use. For example, the Western 
Paciﬁ c region has low overall morbidity from cataracts, 
few cataract operations, and hence especially high 
programme costs per operation; therefore, the cost-
eﬀ ectiveness ratio of cataract surgery is less favourable 
here than elsewhere.22 Estimates in this study were in 
international dollars, which are typically higher than 
estimates in US$ because of the adjustment for 
purchasing power parity.
The reported CERs for surgical interventions are 
especially interesting when compared with widely 
accepted public health strategies in resource-poor 
countries, as estimated by Jamison and colleagues.48 Male 
circumcision in Africa (median CER $13·78 per DALY), 
cataract repair in Nepal ($7·29 per DALY),25 and inguinal 
hernia repair in Ghana ($12·88 per DALY),37 have CERs 
similar to WHO’s Expanded Program on Immunization 
($12·96–25·93 per DALY) and bednets for malaria 
prevention ($6·48–22·04 per DALY). Median CERs of 
cleft lip or palate repair ($47·74 per DALY), general 
surgery ($82·32 per DALY), hydrocephalus repair 
($108·74 per DALY), and ophthalmic surgery ($136·00 per 
DALY) are all similar to that of the BCG vaccine, which 
costs $51·86–220·39 per DALY. We were surprised to 
ﬁ nd that the median CERs of the ﬁ nal two surgery 
categories, caesarean deliveries ($315·12 per DALY) and 
orthopaedic surgery ($381·15 per DALY), were the 
highest of the surgical categories. However, these 
interventions are still excellent value compared with 
medical treatment for chronic ischaemic heart disease 
($500·41–706·54 per DALY) and HIV treatment 
($453·74–648·20 per DALY) under optimum conditions. 
This ﬁ nding is especially relevant in view of the 
magnitude of the disease burden that these surgical 
interventions address. The CERs reported for most 
surgical interventions studied in low-income and middle-
income countries are far below these CERs for widely 
used interventions in these settings.
22 studies assessed particular surgical procedures and 
four studies assessed the overall value of surgical 
facilities. Our systematic search strategy, including 
manual review and rigorous critical appraisal, yielded an 
overview of a wide variety of interventions and provides a 
comprehensive view of the overall cost-eﬀ ectiveness of 
global surgery.
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Figure 5: Surgery versus other public health interventions 
Datapoints are medians, error bars are range. The diamonds and solid lines are for surgical interventions; circles and dashed lines are other public health interventions.
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Because no global consensus regarding modelling 
criteria exists, these studies use very diﬀ erent techniques 
and perspectives to assess costs and health eﬀ ects. Some 
studies used actual cost data whereas others modelled 
costs on the basis of resource use assumptions. Not all 
studies published the breakdown of their costs and, as 
such, we were unable to do adjustments besides currency 
conversion to improve comparability. Although some 
studies use WHO-CHOICE53 or other guidelines to 
establish costs, others have non-standardised inclusion 
of ﬁ xed versus variable costs, provider-level versus 
patient-level costs, and human labour costs. The studies 
that did not include ﬁ xed costs12,14,20,43 or provider fees14,43 
have not incorporated important cost inputs into their 
estimates (appendix). Measurement of the eﬃ  cacy and 
consequences of surgical intervention is not standardised, 
although most investigators used techniques to estimate 
surgical eﬃ  cacy and most also used similar DALY 
calculation methods using Global Burden of Disease 
data. Variation in data quality aﬀ ects the medians 
reported and compared with non-surgical global health 
interventions. However, because we reported median 
values, we feel that we have diminished the eﬀ ect of 
outliers with misrepresentative costs.
Studies included here were of speciﬁ c interventions in 
speciﬁ c countries, and important diﬀ erences exist in costs 
and eﬀ ectiveness across countries. Direct comparison of 
costs and eﬀ ectiveness across studies is diﬃ  cult, although 
we feel we have adequately standardised the reported 
costs by adjusting for inﬂ ation.
Inherent bias exists in the included studies because 
investigators might tend to argue for the cost-
eﬀ ectiveness of surgery, thereby introducing a publication 
bias for positive studies. Moreover, the range of 
interventions studied included a greater proportion of 
low-tech, high-yield procedures (eg, cataract operations 
and circumcision). There might be some surgical 
interventions that have not yet been assessed in low-
income and middle-income settings because their 
infrastructure demands or human-resource requirements 
are, correctly or incorrectly, deemed to be a barrier to 
eﬃ  cient scale-up in the medium term. The interventions 
and populations in the studies included here are not 
exhaustive and further research would be helpful in 
identifying other cost-eﬀ ective surgical interventions in 
other countries.
Findings from the Global Burden of Disease 2010 study 
have shown a rise in the prevalence of non-communicable 
diseases, which include several surgically treatable 
disorders.7,32 Although the MDGs have drawn attention to 
key health issues in low-income and middle-income 
countries and have been able to generate resources for 
and target issues that fall within the MDG framework, 
those that are not included in its agenda are being left 
behind.54 If left unaddressed, these disorders, which 
include most surgically treatable disorders, are likely to 
comprise more than two-thirds of the global years of life 
lost in 2025.7 We therefore feel that the urgent need for 
surgery in global health can no longer be ignored. 
Additionally, our ﬁ ndings refute the long-held idea that 
surgery is not cost-eﬀ ective; nearly all the studies we 
reviewed indicated that surgical intervention can be cost-
eﬀ ective or very cost-eﬀ ective on the basis of WHO 
criteria and compared with accepted public health 
interventions. As the 2015 MDG target date approaches, 
the global health community should focus on 
contemporary health priorities—surgery should be 
included in the post-2015 MDG agenda.
Although these results show cost-eﬀ ectiveness in a 
wide range of settings, many other arguments exist for 
investing in surgical capacity in addition to economic 
eﬃ  ciency. Organisational, ethical, and political arguments 
can also be made for the inclusion of emergency and 
essential surgery as a necessary component of basic 
health-care packages. The Universal Declaration of 
Human Rights provides for health care as a basic human 
right,55 and the International Covenant on Economic, 
Social, and Cultural Rights aims for the “highest 
attainable standard of physical health”.56 The provision of 
emergency and essential surgical interventions should be 
regarded as an essential human right to ensure equitable 
distribution of health care around the world.57 Equitable 
access cannot be achieved in settings where patients are 
forced to incur catastrophic out-of-pocket payments for 
surgical services. Cost-eﬀ ectiveness analysis could 
therefore be an important measure for policy makers to 
consider when deciding how to fund the delivery of 
surgical care.
Surgery in low-income and middle-income countries 
faces implementation challenges. Compared with 
vaccination or antiretroviral treatment, surgery needs 
more infrastructure—eg, clean operating rooms, 
anaesthesia, electrical power for monitoring equipment, 
and ancillary laboratory services. Although most of the 
cost-eﬀ ectiveness analyses we reviewed did appropriately 
attempt to include the cost of such infrastructure, the 
initial infrastructure investment and the recurring cost 
of its maintenance might be a ﬁ nancial obstacle to 
implementation, especially when compared with less 
complex public health interventions. These additional 
costs of implementing surgical programmes should be 
considered when comparing CERs between surgical 
interventions and public health interventions. 
At the same time, although surgery provision can often 
be categorised as a disease-speciﬁ c (ie, vertical) model of 
health-care delivery, it also provides opportunities to 
strengthen long-term, infrastructure-related investments 
(ie, horizontal health-care delivery). So-called diagonal 
development is when vertical inputs ultimately increase 
overall access to and capacity for health systems. Some of 
the most notable successes in global health (including 
vaccination and HIV treatment) have been examples of 
vertical strategies that became diagonal over time. In 
surgery, the missions approach to cleft lip and palate 
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repair is such an example, wherein cleft lip mission trips 
can strengthen health systems through the development 
of surgical infrastructure, training of local workforce, and 
provision of ﬁ nancial sustainability.58
The shortage of health-care providers in resource-poor 
countries is also well documented as a crucial constraint 
on the scale-up of surgical care59–62 and is not typically 
incorporated in cost-eﬀ ectiveness analyses. The restricted 
number of health-care providers, their training cost, and 
the cost of their labour will limit the number of 
interventions that are possible in a low-resource setting in 
the medium-term. Eﬀ orts to expand access to surgical 
interventions should therefore be tailored to the context of 
every country or institution. To help overcome these 
human resource limitations, task-shifting to non-
physicians for some procedures such as caesarean delivery, 
trauma-related procedures, and emergency disorders has 
been shown to be feasible, cost-reducing, and well received 
by physicians in some settings.63–67 Additional eﬀ orts are 
needed to assess barriers to implementation of task 
shifting and to support this approach where appropriate.
The high cost, infrastructure demands, and complexity 
of implementing surgery compared with other public 
health interventions are challenges, but they are not 
insurmountable. Our systematic review shows the high 
value of some surgical interventions in low-income and 
middle-income settings. Thus, cost-eﬀ ectiveness should 
not be perceived as a barrier to expansion of surgery in 
these settings. These challenges can be addressed 
beginning with an emphasis on simple, high-impact 
surgical procedures of the sort documented in the studies 
we reviewed. Mock and colleagues proposed three levels 
of priority for surgical disorders as a road map for surgical 
scale-up.11 The top priority disorders are those that have a 
large public health burden, for which there is a surgical 
procedure that is highly eﬀ ective, and for which the 
surgical procedure (and related ancillary services and 
treat ments) is cost eﬀ ective and feasible to promote 
globally. Some disorders included in this category are 
trauma-related disorders, obstetric emergencies, hernia 
repairs, exploratory laparotomy for acute abdomen, and 
male circumcision. The data presented here suggest that 
cataract surgery would also be classiﬁ ed as a 
priority 1 disorder in areas with a high burden of this 
disease. Priority 2 disorders have a moderate public 
health burden, or are those for which there is a surgical 
procedure that is moderately successful or moderately 
cost-eﬀ ective and feasible to promote globally. Mock and 
colleagues classify evacuation of intracranial haematoma, 
obstetric ﬁ stula repair, thyroid surgery, and mastectomy 
as potential examples in this category. Priority 3 surgical 
disorders have a low public health burden, or are those 
for which there is a surgical procedure that is neither 
highly nor moderately successful at treating the disorder, 
or is low in cost-eﬀ ectiveness and feasibility to promote 
globally. These disorders might include prosthetic 
vascular grafts, parathyroid surgery, transplantation, and 
resections for pancreatic and lung cancers.
Use of this guide to scale up these types of surgical 
interventions, with appropriate consideration of the 
setting, can help to develop the necessary workforce, 
experience, and infrastructure and to motivate stake-
holders for continued expansion to more complex 
surgery. Our ﬁ ndings show that several such surgical 
interventions would be priority 1 interventions. As the 
surgical workforce grows and the beneﬁ ts of surgical 
intervention becomes more widely known as a 
component of basic health care, unit cost will decrease 
further with greater economies of scale and scope, and 
ﬁ nancing mechanisms can be established to enable 
broader access. Such improvement in economic, social, 
and human capital might help to mitigate shortcomings 
in infrastructure, allowing institutions to build surgical 
capacity and provide a selection of priority 2 and 3 
interventions that are less cost-eﬀ ective but valued for 
other reasons.68
Our ﬁ ndings draw attention to the heterogeneity of 
design in cost-eﬀ ectiveness studies of surgical inter-
ventions, and show the need to standardise such research. 
Future studies should make every eﬀ ort to adhere to 
existing WHO-CHOICE guidelines as well as Drummond 
checklists to provide comprehensive, consistent data for 
comparison.10,53 Such standardisation will be especially 
helpful going forward, as new DALY values in 
the 2010 Global Burden of Disease study becomes the 
new standard unit of measurement in future cost-
eﬀ ectiveness analyses.32
Nonetheless, despite methodological heterogeneity, 
nearly all studies still showed the same result: surgical 
interventions are cost eﬀ ective or very cost eﬀ ective. The 
data from these studies lend support to the conclusion 
that a subset of surgical interventions compares very 
favourably to accepted health inter ventions in low-
income and middle-income settings.
As the global burden of non-communicable diseases 
has increased, global surgery has begun to receive 
attention.69 While the perception of surgery as an 
expensive intervention has been a barrier to its 
widespread acceptance in global health in the past, 
available data indicate that investment in surgical care 
delivery is worthwhile from an economic perspective. 
Although surgery requires more specialised human 
resources and infrastructure than many traditional 
public health interventions, when these challenges are 
met, surgery can produce health beneﬁ ts with similar 
cost-eﬀ ectiveness ratios. Findings from this study show 
that many surgical interventions are cost-eﬀ ective to 
very cost-eﬀ ective in resource-poor countries. When 
viewed in the context of a more holistic approach to 
health-system strengthening, surgery can play a pivotal 
part in population-based health-care delivery, and its 
ability to prevent long-term disability in a cost-eﬀ ective 
manner shows its value in the expanding global health 
movement.
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